by Elena Iemma | Aug 10, 2023 | News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...
by Elena Iemma | Oct 17, 2022 | Events
We had a blast at AAPS PharmSci 360 in Boston! Thank you to everyone that attended our talks and poster sessions, and stopped by our booth or cocktail reception at Legal Seafoods! Pictures below! Talks: Anne De Groot, M.D., EpiVax, Inc. Deimmunization and Immune...
by Elena Iemma | Sep 12, 2022 | News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
by Elena Iemma | May 21, 2021 | Events, Webinars
EpiVax CEO/CSO Annie De Groot and Director of Analysis Frances Terry co-presented “Engineering Better Biologics: Does Nature Know Best?” at the 2021 AAPS NBC conference May 19th 2021. Outline: Background on T cells / Immunogenicity EpiMatrix, JanusMatrix ...
by Annie De Groot | Nov 16, 2020 | Events
Dr. Anne De Groot will be participating in the 8th annual AIS “Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases” Dr. De Groot will be speaking on Tuesday Nov 24, during the Track From Preclinical to Drug Approval at...
